A novel approach for reversal of autophagic defects using lysosome-targeted nanoparticles
使用溶酶体靶向纳米颗粒逆转自噬缺陷的新方法
基本信息
- 批准号:9914192
- 负责人:
- 金额:$ 20.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-15 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcidityAcidsAcuteAddressAutophagocytosisAutophagosomeBeta CellButylene GlycolsCaliberCell LineCell physiologyCellsCellular biologyChargeChronicCultured CellsCytosolDataDefectDevelopmentDiabetes MellitusDigestionDiseaseDyesElectron MicroscopyEndocytosisEndosomesEnvironmentExposure toFailureFluorescent DyesFormulationFunctional disorderGlycolsGoalsHeart failureHepatocyteImpairmentIntercellular FluidInvestigationJournalsLabelLipidsLysosomesMitochondriaModelingMonitorNamesObesityOrganellesPatientsPharmacologyPlasmaPolyestersProteinsPublic HealthPublishingQuality ControlRecyclingRoleSuccinic AcidsTechnologyTestingTranslatingcell injurycomorbiditydesignethylene glycolin vivoinhibitor/antagonistinsulin secretioninsulin sensitivitylate endosomeliver functionnanoparticlenon-alcoholic fatty liver diseasenovelnovel strategiesrestorationstemuptake
项目摘要
ABSTRACT
Ample data support a role for impaired lysosomal acidification and reduced autophagic flux in comorbidities
related to obesity, including non-alcoholic fatty liver disease (NAFLD), heart failure, and impaired insulin
secretion in diabetes. Investigation of the role of impaired lysosomal acidification in the pathophysiology of
NAFLD, heart failure, and diabetes has been hampered by the lack of a technology to acidify lysosomes. To
facilitate mechanistic studies of acutely restoring lysosomal pH, we recently published that photoactivated
release of acid from lysosome-targeted nanoparticles (NPs) provides immediate short-term restoration of optimal
pH and autophagic flux. However, to translate such technology for long-term acidification and for in vivo use,
there is a need to develop NPs that release acid independent of an external trigger. This proposal stems
from our development of novel formulations that allow lysosome-targeted NPs to sense their entry into the
lysosomes and then trigger the release of acid. To this end, we capitalized on the observation that impaired
acidification, documented in various diseases, only elevates the pH by 0.6-1 units. Therefore, the pH of the
dysfunctional lysosome is still significantly more acidic than the cytosol and plasma. Consequently, we designed
a new NP formulation that releases acid at pH 6 and below to assure that acid release will only occur in the
lysosome.
We hypothesize that acid-activated-acid-release NPs (acNPs) will allow for continuous treatment and
long-term restoration of lysosomal acidity and autophagic flux. In this study we will develop, test, and
validate acNP in cultured cells. Our long term goal is to develop the acNPs to be used in vivo. Preliminary data
show that the acNPs efficiently target lysosomes. Furthermore, preliminary data in a hepatocyte cell line
demonstrate the capacity of the acNPs to restore pH and autophagic flux under conditions of impaired lysosomal
function induced by chronic exposure to excess lipids. To address our hypothesis we propose the following two
aims: Aim1: Synthesize and characterize lysosome targeted acNPs that activate at pH 6 where we will test
the hypothesis that lysosome targeted acNPs enter the cells through endocytosis and follow them through their
maturation into the lysosome, where at pH ≤6 they will trigger acid release and restore lysosomal pH and
autophagic flux. And Aim 2: Determine the capacity of acNPs to enable long-term restoration of autophagic
flux under conditions that impair lysosomal acidification where we will test the hypothesis that in cells
treated with excess lipid environment, re-acidification of lysosomes by acNP will restore autophagic flux,
mitochondrial turnover, and cellular functions including insulin sensitivity in the hepatocyte and insulin secretion
in the beta cell.
摘要
充足的数据支持溶酶体酸化受损和自噬通量减少在合并症中的作用
与肥胖相关,包括非酒精性脂肪肝(NAFLD)、心力衰竭和胰岛素受损
糖尿病的分泌。溶酶体酸化受损在肝硬化病理生理学中作用的研究
NAFLD、心力衰竭和糖尿病由于缺乏酸化溶酶体的技术而受到阻碍。到
促进急性恢复溶酶体pH的机制研究,我们最近发表了光活化
从溶酶体靶向纳米颗粒(NPs)释放酸提供了最佳的
pH和自噬通量。然而,为了将这种技术转化为长期酸化和体内使用,
需要开发不依赖于外部触发而释放酸的NP。这一提议源于
从我们开发的新制剂,允许溶酶体靶向的纳米颗粒,以感觉到他们进入
然后触发酸的释放。为此,我们利用了观察结果,
在各种疾病中记录的酸化仅使pH升高0.6-1个单位。因此,
功能障碍的溶酶体仍然明显比胞质溶胶和血浆酸性更强。因此,我们设计了
一种新的NP制剂,其在pH 6及以下释放酸,以确保酸释放仅发生在
溶酶体
我们假设酸活化酸释放纳米粒(acNP)将允许连续治疗,
溶酶体酸性和自噬通量的长期恢复。在这项研究中,我们将开发,测试,
在培养的细胞中验证acNP。我们的长期目标是开发用于体内的acNP。初步数据
表明acNP有效靶向溶酶体。此外,肝细胞系的初步数据
证明acNP在受损的溶酶体损伤条件下恢复pH和自噬通量的能力。
由于长期暴露于过量的脂质而引起的功能。为了解决我们的假设,我们提出以下两个
目的:Aim 1:合成和表征在pH 6下活化的溶酶体靶向acNP,我们将在pH 6下测试
假设溶酶体靶向acNP通过内吞作用进入细胞并跟随它们通过它们的内吞作用,
在pH ≤6时,它们将触发酸释放并恢复溶酶体pH,
自噬通量目标2:确定acNP能够长期恢复自噬的能力。
在损害溶酶体酸化的条件下,我们将测试细胞中的假设,
用过量脂质环境处理,acNP对溶酶体的再酸化将恢复自噬通量,
线粒体更新和细胞功能,包括肝细胞中的胰岛素敏感性和胰岛素分泌
在β细胞中。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Modulating lysosomal pH: a molecular and nanoscale materials design perspective.
- DOI:10.36069/jols/20201204
- 发表时间:2020-12
- 期刊:
- 影响因子:0
- 作者:Zeng J;Shirihai OS;Grinstaff MW
- 通讯作者:Grinstaff MW
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK W. GRINSTAFF其他文献
MARK W. GRINSTAFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK W. GRINSTAFF', 18)}}的其他基金
R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma
R21:一种用于治疗鳞状细胞肺癌的新型抗体药物偶联物
- 批准号:
10510002 - 财政年份:2022
- 资助金额:
$ 20.06万 - 项目类别:
R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma
R21:一种用于治疗鳞状细胞肺癌的新型抗体药物偶联物
- 批准号:
10671669 - 财政年份:2022
- 资助金额:
$ 20.06万 - 项目类别:
The Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor Modulation
缺失受体的难题:通过药物受体调节增强功效
- 批准号:
10708018 - 财政年份:2022
- 资助金额:
$ 20.06万 - 项目类别:
Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder
缓释松弛素2治疗肩周炎
- 批准号:
10443323 - 财政年份:2022
- 资助金额:
$ 20.06万 - 项目类别:
Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder
缓释松弛素2治疗肩周炎
- 批准号:
10669219 - 财政年份:2022
- 资助金额:
$ 20.06万 - 项目类别:
A novel approach for reversal of autophagic defects using lysosome-targeted nanoparticles
使用溶酶体靶向纳米颗粒逆转自噬缺陷的新方法
- 批准号:
9752911 - 财政年份:2019
- 资助金额:
$ 20.06万 - 项目类别:
R21: Acidic Nanoparticles for Restoration of Autophagy in Age-associated NAFLD
R21:酸性纳米颗粒用于恢复年龄相关性 NAFLD 中的自噬
- 批准号:
9902306 - 财政年份:2019
- 资助金额:
$ 20.06万 - 项目类别:
Dissolvable Hydrogel Dressing for the Treatment of Burns
用于治疗烧伤的可溶性水凝胶敷料
- 批准号:
9010534 - 财政年份:2016
- 资助金额:
$ 20.06万 - 项目类别:
Synthesis, Characterization, and Evaluation of Polymeric Tissue Lubricants
聚合物组织润滑剂的合成、表征和评估
- 批准号:
8886944 - 财政年份:2014
- 资助金额:
$ 20.06万 - 项目类别:
相似国自然基金
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
- 批准号:22007039
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
- 批准号:
- 批准年份:2019
- 资助金额:10.0 万元
- 项目类别:省市级项目
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
- 批准号:21372217
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
- 批准号:21172061
- 批准年份:2011
- 资助金额:30.0 万元
- 项目类别:面上项目
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
- 批准号:21176225
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
- 批准号:81072511
- 批准年份:2010
- 资助金额:31.0 万元
- 项目类别:面上项目
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
- 批准号:30660215
- 批准年份:2006
- 资助金额:21.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Gene expression regulation in recurrent paediatric acute myeloid leukaemia by characterization of non-coding ribonucleic acids
通过非编码核糖核酸的表征研究复发性小儿急性髓性白血病的基因表达调控
- 批准号:
449784 - 财政年份:2020
- 资助金额:
$ 20.06万 - 项目类别:
Studentship Programs
Study of metabolism of sulfur-containing amino acids as anti-oxidant against the acute exacerbation of interstitial pneumonia
含硫氨基酸抗氧化代谢对间质性肺炎急性加重的研究
- 批准号:
16K19984 - 财政年份:2016
- 资助金额:
$ 20.06万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Omega 3 Fatty Acids Acute Neuroprotection via Mitochondria
Omega 3 脂肪酸通过线粒体提供急性神经保护作用
- 批准号:
9450547 - 财政年份:2015
- 资助金额:
$ 20.06万 - 项目类别:
Omega 3 fatty acids, acute neuroprotection via mitochondria
Omega 3 脂肪酸,通过线粒体提供急性神经保护
- 批准号:
10447712 - 财政年份:2015
- 资助金额:
$ 20.06万 - 项目类别:
Omega 3 fatty acids, acute neuroprotection via mitochondria
Omega 3 脂肪酸,通过线粒体提供急性神经保护
- 批准号:
10297604 - 财政年份:2015
- 资助金额:
$ 20.06万 - 项目类别:
Omega 3 Fatty Acids, Acute Neuroprotection Via Mitochondria
Omega 3 脂肪酸,通过线粒体提供急性神经保护
- 批准号:
10655664 - 财政年份:2015
- 资助金额:
$ 20.06万 - 项目类别:
Omega 3 Fatty Acids Acute Neuroprotection via Mitochondria
Omega 3 脂肪酸通过线粒体提供急性神经保护作用
- 批准号:
8996605 - 财政年份:2015
- 资助金额:
$ 20.06万 - 项目类别:
ACUTE EFFECTS OF OLANZAPINE ON PLASMA LEPTIN, GLUCOSE TOLERANCE FREE FATTY ACIDS
奥氮平对血浆瘦素、无葡萄糖耐量脂肪酸的急性影响
- 批准号:
7951282 - 财政年份:2009
- 资助金额:
$ 20.06万 - 项目类别:
SENSITIVITY TO ACUTE INSULIN MEDIATED SUPPRESSION OF PLASMA FREE FATTY ACIDS
对胰岛素介导的血浆游离脂肪酸急性抑制的敏感性
- 批准号:
7180051 - 财政年份:2005
- 资助金额:
$ 20.06万 - 项目类别:
SENSITIVITY TO ACUTE INSULIN MEDIATED SUPPRESSION OF PLASMA FREE FATTY ACIDS
对胰岛素介导的血浆游离脂肪酸急性抑制的敏感性
- 批准号:
6977013 - 财政年份:2003
- 资助金额:
$ 20.06万 - 项目类别: